Here are five recent research findings:
- Among patients with Type 2 diabetes, GLP-1 medications reduced major adverse cardiovascular events by 13% when compared to a placebo.
- Tirzepatide, the active ingredient in Eli Lilly’s GLP-1 medications Mounjaro and Zepbound, reduced the risk of heart failure by 46% and the risk of both heart failure or cardiovascular death by 38% among individuals with obesity.
- Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death and an 84% lower risk of heart attack compared to patients who did not take either medication.
- The death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11.8% and the heart attack rate was 1.5%, compared to 54% and 6.1%, respectively, for patients who did not take either medication.
- Semaglutide, the active ingredient in Novo Nordisk’s GLP-1 medications Ozempic and Wegovy, reduced annual healthcare costs by $7,502 for patients with overweight or obesity, and by $9,276 for patients with heart failure or atherosclerotic cardiovascular disease.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
